According to FutureWise analysis the market for Remicade Biosimilar in 2023 is US$ 2.99 billion, and is expected to reach US$ 35.3 billion by 2031 at a CAGR of 36.10%.
Biosimilars are biological products that are highly similar to an already approved FDA drug, called a reference biological product. The biosimilars are drugs that have been approved by the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA) and are clinically equivalent to their reference products in terms of safety, purity, efficacy and effectiveness. A biosimilar drug can only be approved for indications and conditions that have already been approved for the reference product by the big regulatory agencies. Remicade (infliximab) is a monoclonal antibody produced by Janssen Biotech Inc. and MerckCo. (MSD) in partnership, and licensed by the U.S. Food and Drug Administration in 1998. Both adult and pediatric patients can use it for the treatment of Crohn's disease. It is also used to treat active ulcerative colitis, moderate to severe rheumatoid arthritis when combined with methroxate, spinal and active psoriatic arthritis, and plaque psoriasis.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Remicade Biosimilar Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Remicade Biosimilar Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.